ETFChannel.com

Why we like health care stocks in 2020

Thu, Jan 9, 11:34 AM ET, by , BlackRock

In a year-end poll of our Fundamental Active Equity investors, two themes stood out: The U.S. election is seen as a key market driver, and health care is among our favored sectors. The two juxtaposed may surprise some readers. Health care reform and drug pricing are hot-button political topics. You might assume it's the year to stay away ― but that could be a hasty diagnosis.

I recently spoke with Erin Xie, lead portfolio manager of BlackRock's Health Sciences Opportunities Fund, to get a temperature check on the sector.

Tony: Let's start with the 800-pound gorilla: How do you see politics affecting health care stocks this year?

Erin: Assessing the implications of the elections on the sector broadly is an imperfect science. There are many complexities associated with each potential outcome.

Much of the conversation has centered around “Medicare for All.” Talk of such a program by some Democratic presidential hopefuls dented health care sector gains somewhat in 2019. We think markets may have overreacted. We see such sweeping health policy changes as too divisive to be a real possibility. Such a program would cost trillions of dollars, and paying for it is a huge challenge. Even Democrats are divided on the topic.

Ultimately, the current political agenda does little to sully our outlook on health care stocks. The sector is underpinned by long-term secular growth drivers, and we see powerful diversification opportunities given limited reliance on economic growth. Health care is a necessity regardless of the economic climate.

Tony: One of those structural growth drivers must be the aging population?

Erin: Absolutely. In 1985, roughly 1 in 12 adults in the U.S. was over the age of 65. By 2025, we expect this proportion will be 1 in 5 ― 20% of the U.S. population. This trend is not unique to the U.S. As health care innovation improves, people are living longer all over the world. These societal shifts are supportive of the sector. Based on our estimates, health care costs roughly triple after age 65. Aging demographics worldwide mean increased health care spending for the years to come ― a fact that is not affected by geopolitical tensions, where we are in the market cycle, or who wins the U.S. election in November.

Tony: What else shapes your positive outlook for the sector?

Erin: There is tremendous innovation happening across the industry. In drug development, for example, biotechnology and pharmaceutical companies are working with years of genomic research. They now have better insight on the cause of diseases, allowing them to develop better products in multiple therapeutic areas, such as in the treatment of cancer, autoimmune disorders and genetic diseases. The American Cancer Society recently reported the largest single-year drop in cancer deaths in the U.S., citing breakthrough treatments for lung cancer.

Meanwhile, digital technology and data science are increasingly permeating the health care space. This has translated into exciting innovation in medical equipment, diagnostic services and robotic surgery. And the use of big data and the application of artificial intelligence are only in their early days in health care.

Finally, we believe emerging countries will increase spending in health care as their economies grow. Developing countries spend a small fraction of their GDP on health care. We estimate a percentage in the low- to mid-single digits compared to teens in developed countries. We expect this gap to close over time.

We see all of these as important drivers of long-term growth.

Tony: You mentioned earlier the sector's limited reliance on the economic cycle. Can you expand on that?

Erin: Health care historically has demonstrated a lower beta (a measure of risk exposure) to global GDP than any other sector. And yet health care is priced at a lower valuation than other defensive sectors such as consumer staples and telecomms. (See the chart below.)

History also shows health care has tended to be a top performer in both late-cycle and recessionary periods. We aren't forecasting a recession, but 10 years into a bull market, it's reasonable to assume we're in the latter stages of the cycle. This typically has been a good time to be invested in health care.

icon-pointer.svgGet Tony's broader outlook for 2020.

But we really believe health care is an all-weather opportunity. The past two years offer a microcosm: In 2019, the sector lagged the broad market but was still up an impressive 23%. And in 2018, health care's resilience was on display: Global equity markets were down 9%, but the sector was up 2%. It's also worth noting that trade disputes have led to increased market volatility, but we've seen limited read-through to the health care sector.

Tony: Before you began investing, you wore a lab jacket. This gives you special insight into the health care sector. How do you apply your training?

Erin: Our team of five has three PhDs in the sciences and one MD. I myself have a PhD in biochemistry. We believe this scientific expertise has given us important advantages in health care investing.

The sector is technologically complicated. Evaluating innovation potential is critical to assessing companies' future prospects. We believe our scientific training gives us an edge in evaluating the strength of the pipeline and technologies. It also affords us the ability to do in-depth due diligence and have productive discussions with R&D executives and physicians. We see this as a differentiator and value-add for our investors.

Tony: I'm a big believer that price matters. How are health care stocks priced currently?

Erin: That's really the sweetener today. Health care will typically trade at a premium to the broader market. That premium has shrunk, making the sector attractively valued versus broader global equity markets and relative to its own history. We believe favorable valuations only strengthen an already compelling investment proposition in the health care space.

Tony DeSpirito is Chief Investment Officer for U.S. Fundamental Active Equity and a regular contributor to The Blog. Erin Xie is a Managing Director and Portfolio Manager of the BlackRock Health Sciences Opportunities Fund.

Returns cited are based on the MSCI All Country World Index (ACWI) and MSCI AWCI Health care Index and sourced from Bloomberg. Valuations (PE ratios) were assessed using Bloomberg data and covering the period from Jan. 31, 1995, to Dec. 31, 2019. Investing involves risk, including possible loss of principal. International investing involves special risks including, but not limited to, currency fluctuations, illiquidity and volatility. These risks may be heightened for investments in emerging markets. Investing in small- and mid-cap companies may entail greater risk than large-cap companies, due to shorter operating histories, less seasoned management or lower trading volumes. Concentrated investments in specific industries, sectors, markets or asset classes may under-perform or be more volatile than other industries, sectors, markets or asset classes and the general securities market. Investments in health services industries may be affected by changes in regulations, advancing technological developments and product liability lawsuits. This material is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of January 2020 and may change as subsequent conditions vary. The information and opinions contained in this post are derived from proprietary and nonproprietary sources deemed by BlackRock to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by BlackRock, its officers, employees or agents. This post may contain “forward-looking” information that is not purely historical in nature. Such information may include, among other things, projections and forecasts. There is no guarantee that any forecasts made will come to pass. Reliance upon information in this post is at the sole discretion of the reader. Past performance is no guarantee of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an index. You should consider the investment objectives, risks, charges and expenses of any BlackRock mutual fund carefully before investing. The prospectus and, if available, the summary prospectus contain this and other information about the fund and are available, along with information on other BlackRock funds, by calling 800-882-0052 or from your financial professional. The prospectus should be read carefully before investing. Prepared by BlackRock Investments, LLC, member FINRA. ©2020 BlackRock, Inc. All rights reserved. BLACKROCK is a registered trademark of BlackRock, Inc. All other marks are the property of their respective owners. USRMH0120U-1051424-1/1

How to use iBonds like a pro
Thu, Feb 27, 5:44 PM ET,
by , BlackRock

Where we stand on factors
Wed, Feb 26, 5:14 PM ET,
by , BlackRock

3 reasons to stick with tech stocks
Fri, Feb 21, 8:04 AM ET,
by , BlackRock

Coronavirus testing our global outlook
Thu, Feb 20, 11:04 AM ET,
by , BlackRock

How disruption is changing the growth vs. value debate
Wed, Feb 19, 9:34 AM ET,
by , BlackRock

More articles:  1 2 3 4 5 6 7 next »

  BlackRock   Erin   Health   This   Tony   believe   care   companies   cycle   from   growth   have   health   information   innovation   investing   investment   market   markets   other   sector   such   that   this   with
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
25 Dividend Giants Widely Held By ETFs
25 S.A.F.E. Dividend Stocks Increasing Payments For Decades
Broker Darlings: Top 15 Analyst Picks of the Dow
Top 25 Broker Analyst Picks of the S&P 500
Forgotten S&P 500 Giants: Analysts' Current Least Favorites
25 Top Ranked Socially Responsible Dividend Stocks
10 Oversold ETFs
The Top 10 DividendRank'ed Stocks
Warren Buffett Dividend Stocks
The DividendRank Top 25
The Top 10 DividendRank'ed DJIA Components
The Top 10 DividendRank'ed Dow Transports Components
The Top 10 DividendRank'ed Dow Utilities Components
The Top 10 DividendRank'ed Nasdaq 100 Components
10 Stocks Going Ex-Dividend
10 Oversold Dividend Stocks
10 Stocks Where Yields Got More Juicy
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Top Ranked Dividend Stocks With Insider Buying
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Metals Stocks You Can Buy Cheaper Than Insiders Did
10 Oversold Metals Stocks
10 Must-Know High-Yield REITs
10 Top DividendRank'ed Financials
10 Top DividendRank'ed Metals Stocks
10 Oversold Energy Stocks
10 Top DividendRank'ed Energy Stocks
10 Top DividendRank'ed Utility Stocks
10 Stocks Crossing Below Book Value
10 Stocks Crossing Above Their 200 Day Moving Average
10 Stocks Crossing Below Their 200 Day Moving Average
10 ETFs Crossing Above Their 200 DMA
The 10 Biggest ETFs
The 10 Best ETF Performers
Best Vanguard ETFs By TTM Performance
Worst Vanguard ETFs By TTM Performance
Best iShares ETFs By TTM Performance
Worst iShares ETFs By TTM Performance
The 10 Worst ETF Performers
10 ETFs With Notable Inflows
10 ETFs With Notable Outflows
Top 10 Analyst Rated Consumer Stocks
Top 10 Analyst Rated Dividend Stocks
Top 10 Analyst Rated Energy Stocks
Top 10 Analyst Rated Financial Stocks
Top 10 Analyst Rated Healthcare Stocks
Top 10 Analyst Rated REIT Stocks
Top 10 Analyst Rated Technology Stocks
Best Dividend Stocks 2000-2020
Best High Dividend Stocks 2000-2020
Top Dividend Stocks 2010-2020
Best High Yield Stocks 2010-2020
Top Dividend Stocks 2015-2020
Top High Dividend Yield Stocks 2015-2020
The Top 10 DividendRank'ed Canadian Stocks
The DividendRank Canada Top 25
10 Canadian Stocks Going Ex-Dividend
10 Oversold Canadian Stocks
10 Canadian Stocks Where Yields Got More Juicy
10 Must-Know High-Yield Canadian Real Estate Stocks
10 Top DividendRank'ed Canadian Financials
10 Must-Know High-Yield Canadian Energy Stocks
10 Canadian Stocks Crossing Below Book Value
10 Canadian Stocks Crossing Above Their 200 Day Moving Avg
10 Canadian Stocks Crossing Below Their 200 Day Moving Avg
Stock market game

Why we like health care stocks in 2020 | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.